A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome | MicrobiomeTrials← Back to trialsNCT07181837
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-29Est. Completion: 2028-03-31
Enrollment target: 12 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Angelman Syndrome
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman …
Los Angeles, United StatesCompleted Feb 2029
Angelman Syndrome
The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.
Los Angeles, United StatesEst. completion Jan 2030